�
SHR3680 � GT0918 ( Proxalutamide ) � ONC1-13B
‣ Other early stage pipeline Antiandrogens and our view – � �
DR103
AZD3514 � HE3232 ( Apoptone ) �
BMS-641988
‣ Androgen Synthesis inhibitors : TAK-700 and TOK-001 Failure in clinical trials creates “ No hope ” for VT-464 & other Cyp17 lyase inhibitor ?
� TAK-700- How it is different from Zytiga ? � GALATERONE ( TOK-001 ) � �
VT-464 ASN001
For More Info : https :// marketreportscenter . com / reports / 505877 / prostate-cancernewer-antiandrogens-emerging-therapies-targeting-a-watchfulwaiting-and-resistance-population
‣ Selective Androgen Receptor Degraders
� GTX-758
‣ Indirect near term key competitors to Zytiga / Xtandi in Post chemo setting : � � �
OGX-011 TAS-3681 ARV-330